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ABSTRACT
Diabetic Ketoacidosis (DKA) is associated with pediatric cerebrovascular-related
complications. DKA-associated inflammation instigates leukocyte adherence to the brain
microvascular endothelium. As adhered leukocytes release enzymes that compromise
vascular integrity, we questioned a role for leukocyte-derived matrix metalloproteinases
(MMPs) and azurophilic enzymes (elastase, proteinase-3, myeloperoxidase). Our aims
were to measure leukocyte-derived enzymes in DKA plasma, determine associations with
DKA severity and investigate their effect on the cerebrovascular endothelium.
Plasma was obtained from children with type-1 diabetes, either in acute DKA or
insulin-controlled. DKA was associated with altered plasma levels of ↓MMP-2, ↑MMP8, ↑MMP-9 and ↑TIMP-4, which are largely leukocyte in origin. DKA was also
associated with elevated plasma leukocyte elastase, proteinase-3 and myeloperoxidase.
MMP-8, MMP-9 and proteinase-3 were positively correlated with DKA severity.
Azurophilic enzymes decreased ZO-1 and degraded β-catenin in cerebrovascular
endothelium.
In summary, DKA is associated with dynamic regulation of leukocyte proteolytic
enzymes that can impair blood brain barrier integrity.
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CHAPTER 1: INTRODUCTION
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1.1 Type 1 Diabetes Mellitus
Type 1 diabetes mellitus (T1DM) is a serious affliction that persists throughout life
(4). Globally, the incidence of T1DM varies greatly, anywhere from 0.5-30.3/100 000
people per year with significant ethnic diversity (5). T1DM occurs predominantly in
children younger than 15-18 years of age and in the past few decades, its incidence has
been increasing (5, 6). Among juveniles with diabetes mellitus, T1DM accounts for over
90% of the cases (7). Cases of T1DM account for 5-10% of all diabetics (4).
Approximately 14.9 billion dollars is expended on T1DM annually, thus treatment and
management of T1DM is of great significance to patients, healthcare professionals and
researchers globally (8).
T1DM is a condition caused by the destruction of the β-cells of the islets of
Langerhans in the pancreas. These cells are responsible for all insulin production in the
body and their destruction leads to an insulin deficiency. A lack of insulin results in an
inability to regulate blood glucose effectively, leading to chronic hyperglycemia. T1DM
is generally classified into 2 categories: Type 1A is the result of an autoimmune response
destroying the β-cells whereas Type 1B is idiopathic destruction of the β-cells (4). Type
1A diabetes mellitus has a predominantly genetic origin where polymorphisms in genes
residing in the human leukocyte antigen (HLA) loci, the insulin-variable number tandem
repeat (VNTR) and cytotoxic T-lymphocyte-associated protein (CTLA)-4 genes can
confer susceptibility to T1DM (9, 10). The other facet of T1DM susceptibility involves
environmental triggers that initiate the immune-mediated destruction of the β-cells in
those already predisposed to it. Examples of triggers include viruses such as rubella,
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environmental toxins such as N-nitroso compounds and food components such as cow’s
milk proteins (11, 12).
Symptoms of T1DM include polydipsia, polyphagia, weight loss, blurred vision,
polyuria with glycosuria and fatigue. The symptoms of T1DM start to present themselves
after approximately 90% of the β-cells have been destroyed (7). Therefore, by the time it
is detected by clinicians, patients are already suffering from a severe insulin deficiency.
Complications that can arise from uncontrolled blood glucose in T1DM are hypokalemia,
hypophosphatemia, hypoglycemia, peripheral venous thrombosis, mucormycosis,
rhabdomylosis, acute pancreatitis, acute renal failure, sepsis and aspiration pneumonia
(13). Longer term complications include retinopathy, nephropathy, neuropathy,
cardiovascular disease, cognitive impairment and increased susceptibility to certain
infections (14). The most severe acute complication of T1DM is diabetic ketoacidosis
(DKA).
1.2 Diabetic Ketoacidosis
DKA involves the breakdown and metabolism of fatty acids and amino acids for
energy. It is caused by a severe deficiency in insulin together with altered levels of
counterregulatory hormones such as catecholamines, glucagon, cortisol and growth
hormones. Increased glycogenolysis and gluconeogenesis along with impaired glucose
uptake by peripheral tissues results in a hyperglycemic and hyperosmolar state (15, 16).
Increased serum glucose levels, beyond that which renal excretion is able to rectify,
causes osmotic diuresis and depletion of electrolytes, leading to potentially fatal
dehydration (15). Occurring concurrently is the metabolism of fatty acids in the liver to
the ketone bodies, β-hydroxybutyrate and acetoacetate, which accumulate in peripheral
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circulation, overwhelming the bicarbonate buffering system and contributing to metabolic
acidosis. Clinically, DKA manifests with dehydration, Kussmaul respiration, nausea,
vomiting, acute abdominal pain and reduced or loss of consciousness (15). Children who
develop DKA possess a higher risk for intracranial vascular complications such as
cerebral edema (17), hemorrhage (18) and stroke (19).
The biochemical criteria for DKA involves hyperglycemia (blood glucose > 11
mmol/L), venous pH < 7.3 or bicarbonate < 15 mmol/L and ketonemia or ketonuria (15).
DKA is classified according to the severity of acidosis: Mild DKA is distinguished by a
pH < 7.3, moderate DKA is distinguished by pH < 7.2 and severe DKA is distinguished
by pH < 7.1 (20).
DKA often occurs in “first time” diabetics, in undiagnosed and therefore, untreated
T1DM cases. Other common events that precipitate DKA are the accidental or deliberate
stoppage of insulin treatment (i.e., weight control in adolescents). Risk factors for DKA
are extremely variable, including children with poor metabolic control, peripubescent
females, children from troubled households and children with psychiatric disorders (21).
1.3 DKA Cerebral Edema
DKA, though a previously highly lethal condition, following the advent of insulin,
has become much more manageable with a mortality rate below 2% (16). However, DKA
still retains significant mortality due to related complications, one of which is cerebral
edema (DKA-CE). DKA-CE is a serious and highly lethal condition, despite advances in
management techniques. In North America, the incidence of DKA-CE among DKA cases
is 0.5-0.9% with a devastating mortality rate of 21-24% (17, 22, 23). Some studies have
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even reported a mortality rate of up to 90% (24). DKA-CE is the leading cause of death
in pediatric cases of T1DM and leaves 30-40% of survivors with significant neurological
damage (25). It has been surmised that DKA-CE mortality accounts for 80% of all
diabetes-related deaths among children under 12 year of age (24). Ninety-five percent of
DKA-CE patients are under 20 years of age and 33% are under 5 years of age (25). As
such, DKA-CE is considered mainly a pediatric pathology. The reason for the apparent
predisposition in children to this complication is not yet clear.
Cases of DKA-CE usually occur within 2-24 hours after the onset of DKA
treatment. Patients present with a sudden headache and reduced level of consciousness
followed by rapid neurological degeneration and eventual herniation of the brain stem
(13, 26). Thus, many researchers suspect DKA-CE to be a side effect of the interventions
traditionally administered for DKA. However, it should be noted that cases of DKA-CE
have been reported before the initiation of treatment (17, 22). Therefore, the etiology of
DKA is more complex than just an adverse response to treatment. DKA-CE can manifest
itself in two ways: from admission, the patient’s condition will steadily deteriorate into a
comatose state or, more frequently, the patient will appear to recover and then suddenly
worsen (24, 27).
Much discussion has centered over the distinction between subclinical and
symptomatic cerebral edema. In a study done on 6 children between the ages of 11 and
14 years old with DKA who were asymptomatic for DKA-CE, it was discovered that all 6
showed evidence of cerebral swelling via computerized tomography (CT) scans taken at
the onset of treatment and at hospital discharge (28). Additionally, another study using
brain encephalography detected the presence of significant cerebral swelling in 81% of
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patients between the ages of 13-42 years old undergoing treatment for DKA, despite the
absence of symptomatic cerebral edema (29). Taken together, these studies suggest that
DKA-CE is far more common in pediatric cases of DKA than previously suspected.
Conversely, another study evaluated ventricle size via CT following DKA treatment in
patients 4-15 years old and found that subclinical DKA-CE did not occur frequently (30).
These controversial findings may be explained by DKA-CE possessing a spectrum of
severities from mild subclinical DKA-CE to severe symptomatic DKA-CE (31).
Cerebral edema can be classified into 2 main categories: vasogenic edema and
cytotoxic edema. Vasogenic edema is the flow of water into the extracellular space due to
destabilization of the Blood-Brain Barrier (BBB). Cytotoxic edema is the flow of water
into the intracellular space resulting in cell swelling (32). Though both cytotoxic and
vasogenic edema are observed in pathological conditions, it has been suggested that the
primary form of edema present in DKA, prior to treatment is that of the vasogenic type.
Diffusion-weighted magnetic resonance imaging (MRI) of pediatric cases of DKA
showed elevated brain apparent diffusion coefficient (ADC), indicating vasogenic edema
(33, 34).
The exact cause of DKA-CE is still largely unknown at this point, though theories
that have been proposed include increases in BBB permeability, increases in hydrostatic
pressure due to aggressive fluid resuscitation concomitantly with decreased osmotic
pressure, loss of cerebral autoregulation, osmotic disequilibrium from accumulation of
intracellular osmoles in the brain, hypoxia and ischemia and intracranial acidosis (35).
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A suggested mechanism of DKA-CE and perhaps the most convincing is the
initiation of a pro-inflammatory cytokine cascade that results in BBB dysfunction.
Observed consistently in DKA is an inflammatory cascade similar to that of systemic
inflammatory response syndrome (36). This inflammatory cascade may trigger transient
opening of the BBB. DKA has been shown to initiate a widespread inflammatory cascade
involving the cytokines, C-X-C motif ligand (CXCL)-1, CXCL-8 and interferon (IFN)-α2
(37). The same study also showed increased adherence of polymorphonuclear neutrophils
(PMN) to the endothelium, providing convincing evidence of leukocyte involvement.
Also reported to be upregulated in patients suffering from DKA are interleukin (IL)-1β,
IL-6, IL-2 and tumor necrosis factor (TNF)-α, whose increase correlates with the
timeframe of the development of subclinical DKA-CE (38). An immunological response
during DKA is further supported by the detection of elevated levels of components of the
complement pathway (C3a, Bb and C5b-9) (39) as well as C-reactive protein (CRP) (40).
In juvenile mice, DKA increased circulating levels of numerous endothelial-specific
molecules such as E-selectin, intracellular adhesion molecule (ICAM)-1 and vascular cell
adhesion protein (VCAM)-1, indicating an onset of systemic inflammation (41). Thus,
the onset of DKA involves a significant activation of the inflammatory cascade. It is well
established that cytokines and the inflammation cascade lead to activation of the BBB
endothelium as well as leukocytes and subsequent BBB disruption, resulting in increased
water flux into the brain, hence the prevalence of cerebral edema in DKA (42-45).
Furthermore, it is believed that acidosis per se plays an important role in DKA-CE.
The ketone bodies, acetoacetate and β-hydroxybutrate are known to be pro-inflammatory
agents that activate the endothelial cells in the BBB by increasing endothelin (ET)-1 and
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vascular endothelial growth factor (VEGF) secretion (46). Both VEGF and ET-1 are
known as vascular permeability inducing factors. In another study, acetoacetate was
shown to increase expression of ICAM-1, a receptor that mediates leukocyte adhesion to
the endothelium (47). Thus, ketone bodies are able to trigger inflammatory processes at
the BBB endothelium and lead to the release of permeability inducing factors.
Hyperglycemia, present during precipitation of DKA can initiate an inflammatory
response as well. Hyperglycemic crises were associated with increased levels of
circulating CRP, free fatty acids, CXCL-8, IL-6, IL-1β and TNF-α (48). Hyperglycemic
conditions can also facilitate the activation of human T-lymphocytes, thus providing a
mechanism by which hyperglycemia is able to trigger inflammation (49). Therefore, not
only DKA, but also hyperglycemia per se is able to trigger an inflammatory response in
the body by facilitating the production and release of circulating cytokines. The
activation of the BBB endothelium by many of these cytokines leads to an increase in
permeability of the BBB.
Some studies have also addressed the role of hypoxia and ischemia in the
development of DKA-CE. Factors like increased blood urea nitrogen (BUN) levels (17),
and lower pCO2 levels (22) have been frequently associated with the development of
DKA-CE. Studies have also shown that cerebral blood flow is decreased in rats with
untreated DKA and that cerebral blood flow was directly tied to pCO2 (50). DKA
commonly results in dehydration which could lead to, in combination with a low pCO2,
increased vasoconstriction and consequently cerebral ischemia, hypoxia and increased
capillary permeability (24, 51, 52). Increased capillary permeability would result in
increased fluid flux across the BBB into the brain resulting in cerebral edema.
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Several studies have attributed DKA-CE occurrence to rapid osmolar changes
resulting from intravenous infusion during treatment (53-55). In a hyperosmolar
environment, such as that commonly seen in hyperglycemia, cells in the brain generate
intracellular osmoles in order to maintain their volume and osmolarity. Hyperglycemic
rabbits showed an intracellular increase in various ionic solutes, sorbitol, lactate, urea,
amino acids (56) and other idiogenic osmoles since identified as taurine and myoinositol
(57-59). These changes were accompanied by equalization of brain and cerebrospinal
fluid osmolality. When the hyperglycemia was corrected, the rabbits rapidly developed
an osmotic gradient from brain to plasma, showed an increase in unidentified osmoles
and other solutes in brain cells, an increased cerebral water content and most
significantly, precipitation of cerebral edema (56). During treatment for DKA with fluids
and insulin, plasma osmolarity decreases rapidly and if the intracellular osmoles do not
dissipate accordingly, the result is that brain cells become relatively hyperosmolar to the
serum, thus favouring inward fluid flux and consequentially, the formation of cytotoxic
DKA-CE.
Another proposed theory behind the pathophysiology of DKA-CE is the
involvement of aquaporin channels, likely the result of fluid administration. Aquaporin
channels are transmembrane channels whose function it is to transport water from
extracellular to intracellular compartments. They are expressed in many epithelial and
endothelial cells throughout the body as well as glial cells of the BBB. Aquaporins are
highly expressed in the endfeet of astrocytes in contact with the abluminal surface of the
cerebral endothelial cells (60). Aquaporin activity is pathologically associated with the
formation of cerebral edema after injury in rats, both vasogenic and cytotoxic(61). They
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have been shown to mediate cerebral edema in other pathological conditions such as
traumatic brain injury and cerebral ischemia (61, 62). Acidotic conditions were shown to
worsen cerebral edema in rats through the actions of aquaporin-1 (63).
1.4 Blood-Brain Barrier
The BBB is present in all mammals with a complex nervous system and plays a
crucial role in keeping the brain isolated from peripheral circulation. The
microvasculature in the brain provides a massive combined area for blood-brain gas,
nutrient and waste exchange. A large functional surface area is critical due to the brain’s
role as the most metabolically active organ in the body. With an average vessel diameter
of < 8 µm, the microvessel functional area for blood-brain exchange in humans is
approximately 100-200 cm2/g in brain tissue, or approximately 12-18 m2 total in an
average adult (64). The BBB does not protect the areas of the brain involved in
autonomic nervous control and endocrine function; it is present in every region of the
brain except the circumventricular areas (65).
The BBB is not a single protective brain partition as its name might imply, rather
it refers to protective and exclusive characteristics that is inherent to brain vasculature
itself, specifically the microvasculature. The BBB is composed of multiple cell types
such as endothelial cells, astroglia and pericytes (66). The spatial arrangement of the
BBB is very distinct. The luminal side of the barrier is composed of the cerebrovascular
endothelial cells (CVEC) which form the vessel wall (Figure 1-1). The CVEC are
arranged continuously, associating tightly together to form the tubular structure of the
vessel. On the abluminal side of the vessel, underlying the CVEC is basal lamina which
sheaths the capillary. Discontinuously associated with this surface are pericytes and
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perivascular macrophages (45, 66). Further into the parenchyma are astrocytes, which
project long endfeet onto the abluminal surface of the CVEC, and microglia (Figure 1-1).
Astrocytes are the most abundant cell type interacting with CVEC and covers a majority
of the microvascular abluminal surface (67). In terms of function, the term BBB refers to
the actions and effects of the CVEC and to a lesser extent, pericytes and astrocytes (45,
66).
The main function of the blood-brain barrier is twofold. The first is to protect the
brain and sensitive neural tissue from neurotoxic compounds, soluble factors,
microorganisms, proteins and other cells that might be present in peripheral circulation.
The second is to maintain homeostatic conditions in the neuronal extracellular
environment by regulating the passage of blood-borne compounds into the brain
parenchyma. In order to fulfill these roles, the BBB must be selectively permeable; it
needs to be able to restrict entry of blood-borne macromolecular compounds with
extreme prejudice, but at the same time, allow essential nutrients and compounds that the
brain needs to function to access the brain parenchyma. The BBB accomplishes this
through physical barriers and expression of selective transporters (64). Transporters
specific for many important substances have been identified in the BBB, including ones
specific for glucose compounds, amino acids, cholines, purines and monocarboxylic
acids (68). The BBB functions to isolate cerebral circulation from peripheral circulation
under physiological conditions. There are many macromolecules present in peripheral
circulation that would be harmful to the brain. Proteins and factors such as albumin,
prothrombin and plasminogen, if allowed to access the brain, are potent signalling
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activators and can stimulate unwanted cell processes, resulting in damage and cell death
(69-71).
The BBB must also exclude peripheral neurotransmitters from the brain. Since both
the central and peripheral nervous signalling uses the same neurotransmitters, it is
imperative that the two systems remain independent of each other. Likewise, this also
prevents excitotoxicity due to peripheral neurotransmitter imbalances spreading to the
brain and disrupting signalling (72). The BBB also excludes immune cells from the
cerebral environment. Activated immune cell infiltration into the brain can damage
delicate neural tissue by releasing destructive factors and enzymes and turning on
unwanted signalling pathways. As such, under normal physiological conditions, the brain
is normally excluded from peripheral immune surveillance (72).
Another function of the BBB is ion regulation. The BBB possesses a multitude of
ion channels and transporters that preserve the ionic composition of the brain and keeps
the extracellular space optimal for neuronal signalling. It is essential to keep the brain
ionic content separate from peripheral ionic concentrations. For example, K+, an
important ion in nervous signalling is held at ~2.5 mM in the brain, in spite of ionic
fluctuations occurring in the periphery (64).
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FIGURE 1-1. Schematic Diagram of the Blood-Brain

Barrier. The BBB is found at the level of cerebral microvessels.
Composing the wall of the vessel itself are continuous CVEC,
tightly

sealed

against

each

other.

Pericytes

are

located

discontinuously on the abluminal side of the endothelial cells
within the endothelial basal lamina. Perivascular macrophages also
share this location. Extending cellular processes to make contact
with the vessel from the neuropil are astrocytes. TJs and AJs
function to seal the gaps between the adjacent endothelial cells.
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1.5 Cerebrovascular Endothelial Cells
The component of the BBB that is most responsible for its exclusionary properties
are the CVEC. CVEC differ from endothelial cells elsewhere in the body by their relative
lack of fenestrae. Fenestrae are pores that go through endothelial cells which allow for
rapid exchange of material between blood vessels and the extracellular space without the
use of transporters or channels and so in CVEC, this lack of fenestrae act to greatly
reduce paracellular movement of substances, lending to the BBB’s permeability
characteristics (45, 66).
CVEC possess tight junctions (TJ) which are complexes of transmembrane
proteins whose primary purpose is to hold adjacent endothelial cells together and
accordingly, they span the intercellular gap between adjacent endothelial cells. The TJs
are also heavily involved in signal transduction in the cells. TJs are composed of a chain
of many, almost continuous, but discrete points of intercellular contact, which are
mediated by protein complexes. These are arranged in a belt-like formation around the
apical end of the cell (45, 73). These points of tight contact between adjacent cells
essentially occlude the paracellular passage. TJs act to increase electrical resistance
across the endothelial layer as well as hindering paracellular transport of soluble
compounds (45). TJs lend the BBB the functional properties of a single continuous cell
membrane (64). This belt imparts polarity upon the cell by physically partitioning the
apical and basal ends, allowing directional transport via asymmetrical expression of
transporter proteins. TJs in the brain differ from those elsewhere in the body by being far
tighter and more complex (64).
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Tight junctions are composed of high levels of intercellular spanning
transmembrane proteins, occludin and the claudins and the intracellular component,
zonula occludens proteins (ZO) (Figure 1-2) (64). Occludin expression is higher in BBB
TJs than in any other peripheral TJ, indicating a central role in the BBB (74). Of the over
20 isoforms of claudin, only claudin-1 and -5 have been shown to be a component of
BBB TJs (65). Both occludin and claudins are directly associated with the cytoplasmic
scaffolding and signalling proteins ZO-1, -2, -3 and cingulin (64, 75). The TJ-ZO
complex is also connected to the actin cytoskeleton. Many studies have associated
disruption of occludin, claudin and ZO-1 with impaired BBB function (76-78). The final
proteins involved in the TJs are junctional adhesion molecules (JAM). JAMs engage in
heterogeneous and homogenous binding across the intercellular gap. Only JAM-A and -C
are involved in the BBB TJs (79). Accordingly, the JAM family decreases BBB
permeability and has been associated with an increased transendothelial electric
resistance, inhibition of leukocyte extravasation and occludin localization (80).
Another important feature of the CVEC in the BBB is the presence of adherens
junctions (AJ). AJs are composed of transmembrane proteins called cadherins, anchored
to the actin cytoskeleton in the cytosol via the catenins (α, β and γ) (Figure 1-2). In the
intercellular space, vascular endothelial (VE)-cadherins homogenously bind to their
adjacent cell counterpart, anchoring the 2 adjacent cells together (81). AJs play a role in
cell-cell adhesion, signalling and transcriptional regulation (82). Perturbances to AJs have
been shown to facilitate disruption of the endothelium (83, 84).
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FIGURE 1-2. Schematic Diagram of the CVEC Junctional
Complexes. Tight junctions are composed of three main proteins:
occludin, claudin and junctional adhesion molecules (JAM). Intracellularly,
these proteins are connected to the cytoskeleton by ZO-1. The junctional
complex also consists of adherens junctions, which are composed of VEcadherin, α-catenin and β-catenin. Together, they are responsible for
physically sealing adjacent endothelial cells together in order to prevent
paracellular movement of luminal solutes as well as playing a role in signal
transduction. (1)
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1.6 Matrix Metalloproteinases
Matrix metalloproteinases are a family of more than 20 zinc2+ dependent
endopeptidases, found both secreted into the extracellular environment and membrane
bound. In humans, there are 23, a number which includes the collagenases (MMP-1, -8, 13, -18), the stromelysins (MMP-3, -10, -11), the matrilysins (MMP-7, -26) and the
gelatinases (MMP-2, -9), as well as the membrane-type MMPs anchored to the cell
surface by a C-terminal transmembrane domain (MMP-14 [MT1-MMP], -15 [MT2MMP], -16 [MT3-MMP] and -24 [MT5-MMP]) or a glycophosphatidylinositol (GPI)
anchor (MMP-17 [MT4-MMP] and -25 [MT6-MMP]) (85-87).
All MMPs are synthesized as preproenzymes with an endoplasmic reticulumtargeting signal peptide and secreted as inactive zymogens or active enzymes (88). In
terms of primary structure, MMPs are composed of several domain motifs, depending on
the specific MMP. The catalytic domain is approximately 170 amino acids long and
contains a zinc-binding motif inside the catalytic cleft (Figure 1-3). The zinc ion binds to
a water molecule and is activated by a glutamate residue also located in the catalytic
domain, in order to hydrolyze the target peptide bond (89). The propeptide domain,
approximately 80 amino acids, is located at the N-terminus and is conserved among the
MMP family (Figure 1-3). It contains a cysteine residue, also known as the cysteine
switch that is able to bind to the catalytic site in order to suppress the proteolytic activity
of the site in the propeptide. Some MMPs have a furin cleavage site between the prodomain and the catalytic domain. These enzymes are secreted in their active forms (90).
Thus, the propeptide domain’s function is to maintain the inactivity of the MMP’s
catalytic domain. Most MMPs contain a C-terminal hemopexin-like domain as well
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(Figure 1-3), which functions mainly as a recognition site for specific substrates, though
most MMPs retain their proteolytic activity without it (91). The hemopexin domain is
however, absolutely necessary for the degradation of triple helical collagen (92).
Similarly, the gelatinases have a series of three fibronectin type II inserts in the catalytic
domain which function to recruit and bind gelatin (93). The hemopexin domain in some
MMPs is also involved in mediating activation via other MMPs (94).
Since the MMPs possess extremely potent proteolytic activity, their activity and
expression is regulated at many levels. A large portion of MMP regulation takes place at
the transcriptional level. MMP transcription is under the control of a number of factors
such as activating protein (AP)-1, E26 transformation-specific translocation variant
(ETV)-4, nuclear factor (NF)-κB (95) and hypoxia-inducible factor (HIF)-1α (96). A
feature common to most MMPs is that they are inducible. MMP gene expression can be
enhanced or suppressed by many factors. Examples of inducers of MMP gene expression
are cytokines, growth factors, phorbol esters, actin disrupters, physical stress and
oxidative stress (94, 97). Factors such as interleukins, interferons, epidermal growth
factor (EGF) and basic fibroblast growth factor (bFGF) can all increase expression of
MMPs through activation of the AP-1 or the ETV-4 elements (95). MMP gene expression
can also be downregulated by transforming growth factor (TGF)-β, retinoic acids and
glucocorticoids (94).
Once secreted, MMPs are activated via cleavage of the propeptide domain,
removing the inhibiting cysteine residue from the catalytic cleft (Figure 1-4) (94). This
cleavage can be mediated enzymatically by other MMPs or proteases such as plasmin
(98). Activation can also be mediated non-enzymatically, which involves disruption of
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the inhibitory interaction between the Zn2+ residue and the cysteine residue. Thus, MMPs
may be activated by S-nitrosylation or oxidation without cleavage of the propeptide
domain (99, 100). Reactive oxygen species, mercurial compounds and denaturants may
also nonenzymatically activate MMPs (101, 102). Nevertheless, in vivo, a majority of
proMMP activation is mediated by tissue or plasma proteases. Numerous studies have
suggested that the urokinase plasminogen activator (uPA)/plasmin system is a critical
physiological activator of proMMPs, including proMMP-2, -3, -9, -12 and -13 (103-105).
Catalytic MMP activation can also be mediated by other MMPs. For example,
MT1-MMP, MT2-MMP and MT5-MMP have been shown to activate proMMP-2 (106108). As well, MMP-2, MMP-3 and MMP-13 are able to cleave and activate proMMP-9
(109-111). ProMMP-2 can be activated by MT1-MMP, but this activation is tightly
regulated by the complexing of tissue inhibitor of metalloproteinase (TIMP)-2 and MMP2 in cells (112). It is thought that the TIMP-2 subunit is required for the localization of
the whole complex and thus, MMP-2 localization to the cell membrane where it can then
be proteolytically activated by MT1-MMP (113). Thus, MMPs play a significant role in
the modulation of each other and allow for even tighter regulation of activity.
Once they are activated however, the proteolytic activity of MMPs is modulated
either by nonspecific protease inhibitors, α2-macroglobulin or by a family of endogenous
regulators called tissue inhibitor of metalloproteinases. There are 4 known members of
the TIMP family: TIMP-1, -2, -3 and -4, ranging from 21-30 kDa in size. TIMPs
noncovalently bind to and inhibit MMPs in a 1:1 stoichiometric ratio (114). The
mechanism by which TIMPs inhibit the catalytic activity of MMPs is not well known.
Studies have reported on the interaction between TIMP-1 and MMP-3: TIMP-1 possesses
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a cysteine residue that is capable of chelating the catalytic Zn2+, thus disrupting its ability
to carry out hydrolytic attack on other species. Additionally, TIMP-1 possibly obstructs
any potential substrate binding in MMP-3 (115).
The TIMPs do not show strong specificity for any particular MMPs; each TIMP
can inhibit every MMP physiologically (116). However, differences between the TIMPs
do exist. TIMP-1 and TIMP-2 have been observed to exhibit a preference for MMP-9 and
MMP-2 respectively (117). TIMP-1 shows a lower affinity for the membrane-type MMPs
(118). Additionally, TIMP-2 and TIMP-3 show a lower affinity for MMP-3 and MMP-7
than TIMP-1 (119). TIMP-3 displays a wider range of MMP inhibition than the other
TIMPs. The expression of TIMP-1 and TIMP-3 are thought to be highly inducible,
whereas TIMP-2 expression is mostly constitutive (120).
The major targets of the MMPs are the proteins that compose the extracellular
matrix and basal lamina such as fibronectin, gelatin, collagen and proteoglycans; indeed,
virtually all protein components of the extracellular matrix (ECM) can be degraded by
the MMPs (88). They serve to modulate tissue architecture through turnover of the ECM
and intercellular junctions.
MMPs not only serve to degrade the ECM but also play a role in the generation of
substrate cleavage fragments that have a biological function, and modify, activate or
deactivate signaling molecules during inflammation (121). MMP-1, -3 and -9 have shown
the most potential to regulate chemokine signaling (122). CXCL-8, a major inflammatory
chemokine has been shown to be potentiated via MMP-8 and-9 processing (123, 124).
Another well-known example is the effect of MMP-7 on the generation on CXCL-1
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gradient. MMP-7 is able to release the chemokine into the ECM thereby generating a
gradient to facilitate PMN infiltration. MMPs have also been shown to possess certain
anti-inflammatory actions. For example, the cytokines CXCL-8 and CXCL-1 have been
shown to be degraded and inactivated by MMP-9. Many MMPs can inactivate CXCL-12
as well (125). Furthermore, in addition to inactivating pro-inflammatory cytokines,
MMPs can also further process them into potent antagonists (126). Examples of this are
the processing of CX3CL-1 and MCP-2 by MMP-2, and MCP-1 by MMP-8 (127).
Thus, MMPs represent a bidirectional level of regulation of inflammatory signals.
Despite their important physiological roles, MMPs, through their ability to promote
ECM breakdown and remodeling, have also been implicated in numerous pathologies.
MMPs are also known to be an important contributor to pathological processes like
arthritis, cancer and cardiovascular diseases (128-130). In particular, the gelatinases,
MMP-2 and -9, have been shown to play a critical role in processes such as tumour
invasion, angiogenesis and neovascularisation.
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FIGURE 1-3. Schematic Diagram of the Common Different
Functional Domains of the MMP Family.
S, signal peptide; Pro, propeptide domain; Cat, Catalytic domain; Zn, Zinc
residue; Fn, Fibronectin domain; Hpx, Hemopexin domain; I, Type I
transmembrane domain; Cp, Cytoplasmic region; G, GPI anchor; ■, Furin
cleavage site; V, Vitronectin insert.
Classically, MMPs are composed of 3 main regions, the propeptide domain
which inactivates the enzyme, the catalytic domain which facilitates target
cleavage and the hemopexin/vitronectin domain which facilitates substrate
recognition. Other domains include the signal peptide which locates the
preproenzyme to the endoplasmic reticulum, Type 1 transmembrane domain
and GPI anchor which serve to attach MT-MMPs and the furin cleavage site
which facilitates activation via furin. (2)
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FIGURE 1-4. Schematic Diagram of the Classic Activation of
MMPs. The catalytic activity of the proenzyme is inhibited by the presence
of propeptide domain which binds to and obstructs the catalytic cleft.
Cleavage of the propeptide domain results in dissociation of the inhibitory
complex and allows the MMP catalytic cleft to access and digest substrate.
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1.7 Polymorphonuclear Neutrophils
Polymorphonuclear neutrophils are the most abundant subtype of granulocyte
white blood cell present in mammalian circulation. They are a key component of the
innate immune system whose main role is to defend the body against microbes and
pathogens during inflammation and are considered the “first line of defense”. PMN are
constantly circulating throughout the body, moving through vessels in a nonadherent state
and constantly probing the vascular wall. However, during inflammation, they transition
into an adherent state. The endothelial cells of the vascular wall, upon inflammation,
become activated and express many different membrane proteins such as E- and Pselectin as well as ICAMs (131). The PMN themselves constitutively express L-selectin
and P-selectin glycoprotein ligand (PSGL)-1 which can bind to all 3 types of selectin
(132-134). Coupled with vessel dilation due to inflammation and flow stress, PMN are
allowed to contact the vessel wall (135). Following inflammatory cytokine-mediated
activation of endothelial cells, both expression of E-selectin and ICAM-1 are
upregulated. L-selectin and PSGL-1, expressed on PMN, physically interact with E- and
P-selectin, expressed by the endothelial cell, transiently recruiting the PMN to the
endothelium. The PMN then “rolls” along the endothelium, jumping from selectin
molecule to selectin molecule. Exposure to chemokines quickly triggers PMN to become
more firmly adherent to the endothelium, a state change mediated by leukocyte integrins,
leukocyte-function-associated antigen (LFA) and macrophage-associated protein (MAC)1 on the PMN interacting with ICAM-1 on the endothelial cell (134). The presence of
chemokines during inflammation serves to activate integrins, thus increasing their
binding strength immensely. At this stage, the rate at which PMN roll across the
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endothelium is greatly diminished. Binding of leukocyte integrins to endothelial
immunoglobulin (IgG)-superfamily molecules mediates leukocyte arrest (134, 136). Once
its rolling has been arrested and the PMN firmly adheres to the endothelium, it is able to
respond to inflammatory chemoattractants and undergoes chemotaxis. The PMN can then
transmigrate through the endothelial layer into inflamed tissue, a process actively
facilitated by endothelial platelet-endothelial cell adhesion molecule (PECAM)-1 and
JAMs (Figure 1-5).
PMN are able to coordinate the body’s immune system response as they can
generate chemotactic signalling molecules, TNF and other cytokines such as IL-1β,
monocyte chemoattractant protein (MCP) -1 and CXCL-1 to activate and direct immune
cells (3, 137, 138). They can even direct macrophage differentiation into either a pro- or
anti-inflammatory phenotype (138).
PMN, however, are more recognized for their direct antimicrobial action. The
cadre of microbicidal processes that PMN possess include their phagocytic function, their
ability to release granules filled with proteolytic enzymes and their ability to produce
reactive oxygen species (139, 140). The hallmark of all granulocytes and indeed, PMN,
are the granules which form intracellularly during differentiation in the bone marrow
(141). These granules can be divided into 3 main categories based on the proteins
contained within them: primary/azurophilic granules, secondary/specific granules and
tertiary/gelatinase granules. Azurophilic granules primarily contain myeloperoxidase
(MPO) which facilitates peroxidation of cell membranes, 3 serine proteases, PMN
elastase (HLE), proteinase-3 (PR-3) and cathepsin G (CTSG) as well as defensins and
lysozyme. Specific granules contain lactoferrin, an enzyme that sequesters away iron and
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copper, MMP-8 and lysozyme. Tertiary granules contain MMP-9 and MMP-25 (139).
PMN also possess secretory vesicles which contain plasma proteins, complement
receptor and Fc receptors (142). The type of granule produced coincides with the
differentiation stage of the PMN such that azurophilic granules are indicative of relatively
young PMN while gelatinase granules are that of mature PMN (143). These granules are
released in a process called degranulation which occurs upon activation, during and after
the transmigration of PMN through the endothelial layer into tissue. Different granules
are released at different times during PMN extravasation. Secretory vesicles are
exocytosed upon contact with the endothelium and so act to facilitate a further immune
response (139, 144). In general, the order of granule subtype released depends upon the
ease of mobility. Secretory vesicles are most easily mobilized and are therefore, released
first, onto the PMN membrane within the bloodstream and at the endothelial surface.
Tertiary granules are the second easiest mobilized granule and are released as PMN are
moving through the endothelial layer whereas primary and secondary granules are the
most difficult to mobilize and are thus, released directly at the site of inflammation (3).
The release of these highly destructive enzymes is crucial for antimicrobial activity.
However, unwanted or improper release due to severe inflammation can cause serious
damage to tissue. Pathologically, PMN play a deleterious role in inflammatory conditions
such as ischemia-reperfusion injury and sepsis (145-147).
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FIGURE 1-5. Diagram of PMN Activation and Recruitment to the
Vascular Endothelium. During inflammation, endothelial cells express Pand E-selectin on the cell surface. These proteins interact with ligands on the
PMN resulting in margination and rolling of PMN on the endothelial surface.
Adhesion molecules of IgG-superfamily (e.g., ICAM-1) expressed on vascular
endothelium interact with PMN adhesion molecules (e.g., integrins) resulting
in PMN capture and firm adhesion. Subsequently, PMN migrate across the
endothelial barrier (a process mediated by PECAM-1 and JAMs) in response
to chemotactic stimulus. Once inside the infected/inflamed tissue, PMN
release their vesicles and microbicidal enzymes in a process called
degranulation. (3)
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1.8 PMN Serine Proteases
The PMN serine proteases (NSP), as previously mentioned, include HLE, PR-3
and CTSG. The major sources of these serine proteases are PMN, but also include
monocytes (148, 149) and other granulocytes such as eosinophils (150). Similar to
MMPs, NSPs are expressed as proenzymes (151-153) and require processing into active
forms. However, unlike MMPs which are secreted as proenzymes, NSPs are generally
processed into their active form prior to packaging into their respective granules and are
therefore, active upon release (154).
These homologous proteases depend upon a catalytic triad formed from aspartate,
histidine and serine (154). As its name implies, serine proteases contain a catalytic serine
residue. The catalytic unit utilizes the hydroxyl group on the residue and free H2O to
hydrolyze the target peptide bond (155). They are all neutral proteases with their optimal
pH range being around 7.5-8.5 (154, 156).
Physiologically, they are irreversibly inhibited by the endogenous protease
inhibitor family, the serpins, such as α1-proteinase inhibitor and α1-antichymotrypsin, or
to a lesser extent, α2-macroglobulin (154). Interestingly, α1-proteinase inhibitor displays
specificity for HLE but nevertheless, inhibits all serine proteases (157). A conserved loop
domain on α1-proteinase inhibitor and other serpins, binds to the protease catalytic site.
When the loop is cleaved, the inhibitor undergoes a rapid conformational change,
trapping the NSP and the inhibitor in an inactive state (158). These inhibitors are
extremely prominent in plasma, in far excess of circulating NSPs (157). However, it is
thought that during inflammation, the release of these proteases is significant enough to
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overwhelm the local inhibitory capacity and exert its actions for a brief period of time
(159, 160).
Intracellularly, NSPs are stored in phagolysosomes and act to digest phagocytised
pathogens. They are, however, more recognized for their extracellular role in ECM
destruction and peptide cleavage. NSPs are able to cleave a variety of ECM components
including elastin, fibronectin, laminin, collagens and proteoglycans (161-163). They are
also able to cleave a wide range of plasma proteins such as complement and factor VII
(164, 165). Due to their extremely broad range of overlapping substrates, it is believed
that they are non-specific proteases.
NSPs also play a role in innate immunity (166) and regulation of the
inflammatory response (167). NSPs have been shown to augment the inflammatory
cytokine response. HLE can induce release of CXCL-8 (168-171), IL-33 and GM-CSF
(170). PR-3 has been shown to be able to induce the release of CXCL-8 (171), active IL18 which can promote PMN activation (172, 173), TNF converting enzyme and IL-1β
converting enzyme (174). The NSPs can not only induce cytokine release from other cells
but are also able to modify the biological function of cytokines. For example, both TNF-α
and IL-6 are cleaved and inactivated by all three of the NSPs (175, 176). PR-3 was also
shown to be able to generate more active forms of CXCL-8 whereas HLE was shown to
inactivate it (177, 178). HLE has also been shown to cleave IL-2, a potent T-cell
activator, into inhibitory fragments (179). NSPs may also function to facilitate PMN
transmigration through the endothelium. NSPs could, potentially, be used to degrade
various proteins of the ECM and impeding intercellular junctions (180-182). Interestingly
though, it has been shown in some studies that inhibition of the various NSPs does not
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inhibit neutrophil migration (183), indicating an incomplete understanding of the
mechanism by which PMN penetrate the endothelium.
Pathologic regulation of NSPs has been observed in many diseases such as
ischemia-reperfusion injury, arthritis and emphysema. As powerful proteases, much of
the focus has been on their proteolytic activity. NSPs have been shown to contribute to
lung injury due to its ability to degrade both endothelial VE-cadherin, thereby promoting
microvascular permeability and E-cadherin which contributes to alveolar flooding (184).
HLE has been shown to be associated with fatal sepsis (147) and is thought to function by
disrupting endothelial integrity. This junctional disruption could be mediated by NSPs
(182, 185).
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1.9 Rationale
Pediatric DKA has been linked to numerous intracranial cerebrovascular
pathologies such as vasogenic edema and hemorrhagic stroke (19, 186-189). Although
the exact mechanisms of these crises are not known, a common element to all
cerebrovascular complications is endothelial dysfunction. A prominent theory is that
DKA results in the breakdown or destabilization of the brain endothelium, increasing
endothelial permeability and allowing solutes and water to cross into the extracellular
space. BBB disruption was observed in conjunction with DKA in examination of brain
tissue from 2 deceased human patients. In the same study, DKA was associated with
decreased expression of numerous tight junction proteins such as occludin, claudin-5,
ZO-1 and JAM-A in all areas of the brain, indicating a dysfunction in the formation or
composition of the TJs at the BBB (190). Functionally, increased albumin leakage into
the brain from peripheral circulation was also observed in the study, providing direct
evidence of compromised BBB function.
Pathological MMP activity is widely implicated in BBB disruption (98, 191-193).
Increased MMP expression and activity have been seen in severe sepsis, traumatic brain
injury, cerebral ischemia, bacterial meningitis, stroke and migraine and have been linked
to increased permeabilization of the BBB (96, 192, 194-199). MMPs can contribute to the
disruption of the BBB by directly degrading TJs between the CVEC, leading to increased
water and solute movement across the BBB (200). Increased MMP-2 and -9 activity and
expression was associated with degradation of claudin-5 and occludin in cerebral vessels
following ischemic reperfusion injury in rats, indicating decomposition of the TJs (201).
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MMPs can also contribute to BBB or any endothelial disruption by releasing
permeability-inducing factors that are normally sequestered away in the ECM such as
vascular endothelial growth factor (VEGF), thus facilitating an increase in biological
activity (202, 203). It has also been demonstrated that MMPs are able to proteolytically
activate latent factors such as TGF-β (204), which has been shown to significantly
increase endothelial permeability (205).
MMPs are known to play a role in cytokine processing and generation of
biologically active fragments (127). Processing of the cytokines, CXCL-8, CXCL-5 and
CXCL-6 by both MMP-8 and -9 has been shown to potentiate their chemotactic effects
and biological function (206). MMP-mediated cytokine processing acts to facilitate
leukocyte activation and migration, thus facilitating endothelial disruption indirectly
(127).
Previous work in our lab has shown that DKA is associated with a pro-adhesive
phenotype of endothelial cells (41). DKA also results in increased circulating proinflammatory cytokines such as CXCL-8, CXCL-1 and IFN-α2, which results in
increased activation and adhesion of PMN (37). PMN possess granules full of destructive
enzymes which are released upon activation. PMN-derived MMP-9 can facilitate the
pathological breakdown of the BBB during ischemic-reperfusion injury (191). The PMN
serine proteases, elastase and cathepsin G were shown to be able to induce a disruption of
the BBB and increase vascular permeability in rats (207). Additionally, PMN elastase and
PR-3 were shown to be able to induce apoptosis of endothelial cells (208, 209). Activated
PMN and their associated proteases have been associated with widespread endothelial
damage (207, 210, 211). MPO generates extremely powerful oxidizing species such as
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hypochlorous acid from H2O2 and has been shown to severely disrupt BBB function in
vitro and in vivo (212). It also plays a role in generation of endothelial intracellular
oxidative species and drives apoptosis in some cell types (213, 214).
Similar to the MMPs, the PMN protease are known to play a role in the processing
of cytokines, rendering them either active or inactive. For example, elastase and PR-3 are
known to be able to cleave immunoglobulin, IL-2 receptor (215), TNF-α (175) and TNFα converting enzyme (174). All 3 serine protease also process CXCL-8 and CXCL-1
(177).
Previous experiments done in our lab have shown leukocyte adherence to the
endothelium under DKA conditions indicating significant leukocyte involvement. We
believe that the intracranial vascular complications often seen in DKA are the result of
the destructive enzymes released by adherent leukocytes during the DKA inflammatory
response. Therefore, is it believed that disturbance in the BBB and other endothelial
barriers are exacerbated by the presence of DKA through perturbances in circulating
leukocyte-derived MMPs as well as azurophilic enzymes.

34

1.10 Hypothesis
I hypothesize that children with DKA will present with increased plasma
leukocyte-derived proteases and enzymes compared to insulin-controlled T1DM. In
addition, enzyme levels will correlate with DKA severity and result in brain
microvascular junctional disruption.
1.11 Objectives
I.

To examine plasma MMPs/TIMPs in pediatric DKA patients and to correlate
these with DKA severity.

II.

To (1) examine the systemic PMN azurophilic enzyme profile of pediatric
DKA patients and to correlate these with DKA severity and (2) to examine
the potential for PMN azurophilic enzymes to disrupt brain microvascular
intercellular junctions.
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CHAPTER 2: DYNAMIC REGULATION OF PLASMA MATRIX
METALLOPROTEINASES IN HUMAN DIABETIC KETOACIDOSIS

A version of this chapter has been submitted for review.
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2.1 Introduction
Type 1 diabetes mellitus (T1DM) is a chronic affliction that occurs predominantly
in children, and is expected to double over the next decade (1). The most frequent
complication of T1DM is diabetic ketoacidosis (DKA), a state of insulin deficiency that
leads to metabolic acidosis, hyperglycemia and ketonemia (2). DKA is associated with
intracranial cerebrovascular-related complications such as stroke (3), hemorrhage (4) and
vasogenic edema (5).
DKA is associated with systemic inflammation (6-9). We recently reported that
DKA elicits significant elevations in the chemokines CXCL-1 (GROα) and CXCL-8 (IL8), resulting in leukocyte adhesion to human-derived cerebral microvascular endothelium
(10). Adhered leukocytes can release substances that mediate endothelial damage and
vascular destabilization (i.e., matrix metalloproteinases [MMP]) (11).
MMPs are a family of endogenous proteases that include collagenases (MMP-1,8,-13), stromelysins (MMP-3,-10,-11), matrilysins (MMP-7,-26), gelatinases (MMP-2,-9)
and membrane-type MMPs (MMP-14, -15, -16, -17,-24, -25) (12). Leukocytes are a
major source of circulating MMPs during inflammation (13). Alterations of MMPs and
their endogenous tissue inhibitors (TIMPs) are observed in inflammation-related
pathologies (14-16) and MMPs have potential to compromise cerebrovascular endothelial
barrier function (17-19).
We hypothesized that DKA is associated with elevated leukocyte-derived MMPs.
Our aims, using blood from acute pediatric DKA patients, were (1) to measure plasma
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levels of MMPs/TIMPs, (2) to correlate the MMP/TIMP levels with DKA severity, and
(3) to determine if MMPs are leukocyte-derived.
2.2 Methods
This study was approved by the Health Sciences Research Ethics Board at
Western University. Patients were recruited at our regional tertiary care centre; the
Children’s Hospital, London Health Sciences Centre (London, ON).
2.2.1 Human Subjects
Consent was obtained from the legal guardians of all pediatric patients admitted
with DKA, and both legal guardian consent and patient assent were obtained for T1DM
insulin-controlled patients. Biochemical diagnostic criteria for DKA included
hyperglycemia > 11 mmol/L, bicarbonate < 15mmol/L and ketonurea (20). DKA is
classed according to severity of acidosis as mild DKA (venous pH < 7.3), moderate DKA
(pH < 7.2) or severe DKA (pH < 7.1) (21, 22). The majority of DKA cases used in this
study were severe. Clinic patients with insulin-controlled T1DM (HbA1c < 10% and no
DKA for > 3 months) served as controls (CON).
2.2.2 Blood Collection and Processing
Blood for research purposes was obtained on hospital presentation at the time of
clinically-indicated blood draws. Blood was drawn into citrate-containing tubes
(Vacutainers®, BD Biosciences, Mississauga, ON) by certified nursing personnel, placed
on ice, and immediately transferred to the Translational Research Centre facility for
processing by standard operating procedures (www.translationalresearch.ca, London,
ON) (23, 24). Briefly, blood was centrifuged at 1500 g for 15 min (4oC), and the upper
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plasma layer collected into 250 µl aliquots. Next, the buffy coat was removed and also
aliquoted. Both plasma and buffy coat aliquots were immediately frozen at −80 °C until
usage. When needed for experiments, plasma was thawed and maintained briefly on ice.
Freeze-thaw cycles were avoided.
2.2.3 MMP/TIMP Antibody Microarray
The plasma concentrations of MMP-1, MMP-3, MMP-8, MMP-10, MMP-13,
TIMP-1, TIMP-2 and TIMP-4 were measured using a multiplex enzyme-linked
immunosorbent assay (ELISA)-based array, the Quantibody® Human MMP array
(RayBioTech, Inc.; Norcross, GA) which utilizes a biotin conjugated detection antibody
and a streptavidin-labeled Cy3 equivalent dye that produces a fluorescent signal intensity
proportional to concentration. Undiluted plasma was loaded into each well and assayed
according to the manufacturer’s instructions. The completed arrays were then shipped
back to the manufacturer for data extraction and analysis.
2.2.4 MMP Gelatin Zymography
MMP-2 and MMP-9 were assayed using gelatin zymography, as we reported
previously (16). Plasma samples were diluted 1:1 in PBS. Protein in the diluted plasma
samples was then quantified using the bicinchoninic acid assay (Thermo Fisher
Scientific, Waltham, MA). Equal amounts of protein (75µg) were mixed with nonreducing sample buffer and loaded in each well. Samples were run on a 10% sodium
dodecyl sulphate polyacrylamide electrophoretic gel impregnated with 0.1% gelatin (m/v)
under non-reducing conditions at 140V until the dye front left the gel. Enzymes were renatured in 50mL of 2.7% Triton X-100 (v/v) in distilled water with gentle shaking for 1
hour at room temperature. After washing gels for 5 minutes in 50mL of distilled water on
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a rotary mixer, the gels were developed in 50mL of developing buffer (50mM Tris-base
pH 7.4, 200mM NaCl, 5mM CaCl2·2H2O) containing 1 cOmplete EDTA-free Protease
Inhibitor Cocktail Tablet (Roche Applied Science, Indianapolis, IN) for 20 hours at 37°C
(5% CO2). The gels were then stained with 0.5% Commassie Brilliant Blue R-250
(Roche Diagnostics, Mississauga, ON) for 1 hour and then de-stained with a solution
consisting of 30% MeOH (v/v) and 10% acetic acid (v/v) until bands of proteolysis were
clear. Gels were scanned using a GS-690 densitometer (Bio-Rad Laboratories, Hercules,
CA). Proteolytic bands were quantified as a ratio of the optical density of the
experimental band to a known amount of human recombinant active MMP-2 standard
(EMD Millipore, Etobicoke, ON) run on the same gel. Quantification of bands was
performed using image quantification software (FroggaBio, Toronto, ON). Negative
control zymograms were incubated in the presence of 20 mM ethylenediaminetetraacetic
acid (Bioshop, Burlington, ON).
Since the zymography technique measures protein as gelatinolytic activity as
opposed to concentration, it was necessary to estimate the concentration of MMP-9 from
proteolytic bands in a separate experiment. In order to quantify the MMP-9 present in a
zymogram, identical volumes (1.0 µL) of three representative age- and sex-matched
sample pairs were loaded and run on a zymogram as previously described. A doseresponse curve of a known amount of recombinant human active MMP-9 standard (EMD
Millipore) was loaded and run on the same gel. The optical density of the proteolytic
bands were measured as previously described and the standard dilutions were used to
generate a standard curve to quantify the mass of MMP-9 present in a given proteolytic
band. The plasma concentration (ng/mL) of MMP-9 in each experimental condition was
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estimated by adjusting the average mass of MMP-9 in the zymogram for the volume of
plasma initially loaded in the gel and the dilution factor.
2.2.5 Quantitative Real-Time PCR
Quantitative real-time polymerase chain reaction (qPCR) was used to quantify the
expression of the genes found to be significantly altered in zymography and the ELISA
array. RNA was isolated using TRIzol® LS Reagent (Life Technologies, Grand Island,
NY) from buffy coat extracted from CON and DKA patients then subjected to Turbo
DNA-free (Life Technologies) digest according to the manufacturer's suggested protocol.
The RNA integrity number (RIN) of the samples was assessed using the Agilent 2100
Bioanalyzer (Agilent Technologies, Mississauga, ON) at the London Regional Genomics
Center, samples had an RIN > 6.7. 2µg of RNA from each sample was then reverse
transcribed using iScript™ Advanced Reverse Transcriptase (Bio-Rad). TaqMan® Gene
Expression Assays (Life Technologies) were used with the SensiFAST™ Probe No-ROX
kit (Bioline, London, UK) for qPCR. The assay IDs were MMP-2 (Hs01548727_m1),
MMP-8 (Hs01029058_m1), MMP-9 (Hs00957562_m1) and TIMP-4(Hs00162784_m1).
Target

genes

were

normalized

to

β-actin

(Hs01060665_g1)

and

GAPDH

(Hs02758991_G1). The reaction was carried out with CFX96 Real-Time PCR Detection
System-IVD (Bio-Rad).The PCR protocol was as follows: 2 minute initial denaturation at
95°C, 70 cycles of 10 second denaturation at 95°C, 30 second annealing and extension at
60°C.
2.2.6 Statistical Analysis
All calculations were done using Graphpad Prism software. Data was assessed
with the Mann-Whitney U test for nonparametric data with Bonferroni’s correction for
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multiple comparisons when applicable. Correlation analysis utilized Spearman’s rank
correlation coefficient. All data is presented as mean ± standard error (SEM). Statistical
significance utilized a P value of < 0.05.
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2.3 Results
Study patients
Plasma was obtained from T1DM patients either in an acute DKA or in an
insulin-controlled state (CON). The two groups were age- and sex-matched (n=16/group;
Table 2-1). Patients with DKA had significantly higher HbA1c values, compared to those
with insulin-controlled T1DM (P<0.001), indicating elevated blood glucose over the
previous three months. DKA patients all had elevated blood glucose (27.4±8.3 mmol/L)
and moderate to severe metabolic acidosis (pH 7.00±0.03; PCO2 20.8±2.3 mmHg; HCO35.9±0.8 mmol/L; lactate 2.9±0.7 mmol/L).
ELISA array measurements of plasma MMPs/TIMPs
In order to generate an MMP/TIMP profile, the levels of MMP and TIMP species
were measured in plasma from both DKA and CON groups. Out of all the plasma MMP
and TIMP species measured on the array, only MMP-8 and TIMP-4 were found to be
significantly increased in DKA (17.1-fold increase and 2.1-fold increase, respectively), as
compared to CON (Table 2-1; P < 0.001; n=16 per group). These results demonstrate
selective elevation of the collagenase MMP-8, and to a lesser extent, TIMP-4.
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TABLE 2-1. Clinical Data and Plasma MMP/TIMP Levels in Type-1 Diabetes
Patients.
Either insulin-controlled (CON) or with acute diabetic ketoacidosis (DKA) (n= 16/group)

CON

DKA

P value

11.4 ± 1.0

11.7 ± 0.8

0.830

8:8

8:8

1.000

8.3 ± 0.3

11.7 ± 0.5

< 0.001

MMP-1

1.22 ± 0.72

2.24 ± 1.18

0.865

MMP-3

6.04 ± 1.34

9.45 ± 1.72

0.086

MMP-8a

39.96 ± 12.90

684.25 ± 307.59

MMP-10

0.28 ± 0.04

0.60 ± 0.16

0.181

MMP-13

0.03 ± 0.01

0.04 ± 0.02

0.201

TIMP-1

5.46 ± 1.75

10.70 ± 2.28

0.318

TIMP-2

4.42 ± 0.37

4.71 ± 0.47

0.925

TIMP-4

1.08 ± 0.12

2.26 ± 0.22

< 0.001

Clinical Data
Mean age (years)
Male: Female
ratio
HbA1c
MMP/TIMP
Microarray

< 0.001

a; Concentrations of MMP-8 are reported in pg/mL (mean ± SEM). All the rest
are all reported in ng/mL (mean ± SEM). To control for repeated measures in
MMP/TIMP analyses, a P value<0.005 was considered significant. Boldface
indicates significant P value.
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Gelatin zymography for MMP-2 and MMP-9
To assess MMP-2 and MMP-9 levels in DKA, we assayed gelatinolytic activity of
both CON and DKA plasma via zymography. A representative zymogram of 3 different
CON/DKA sample pairs is shown in Figure 2-1A. MMP-9 was significantly increased
1.7 fold in DKA plasma compared to CON plasma (Figure 2-1B; ~100 kDa MW; P <
0.05). Conversely, MMP-2 was significantly decreased 2.8 fold in DKA plasma
compared to CON plasma (Figure 2-1C; ~70 kDa MW; P < 0.001). In addition, DKA
plasma had a faint ~135 kDa band on gelatin zymography that may reflect a welldescribed complex of MMP-9 with neutrophil-gelatinase-associated lipocalin (25).
Overall, these results suggest distinct opposing regulation of the MMP gelatinases by
DKA in children, and a potential neutrophilic source of MMP-9.
The plasma concentration of MMP-9 was estimated from zymography (data not
shown) using 3 age-/sex-matched sample pairs (CON ~670 ng/mL vs. DKA ~1,509
ng/mL).
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FIGURE 2-1. Gelatin Zymography of DKA Plasma. Gelatin zymography was used
to measure both MMP-2 and MMP-9. (A) A representative zymogram of 3 plasma
DKA/CON experimental pairs. The right-most lane contains a molecular weight ladder.
MMP-9 is represented at ~100 kDa, likely representing the latent form. MMP-2 is
represented by the bands at ~70 kDa, also representing the latent form. (B) MMP-9 levels
in DKA plasma were significantly increased relative to CON plasma. Results are
presented as relative optical density. (C) MMP-2 levels in DKA plasma were
significantly decreased from CON plasma. Results are presented as relative optical
density. *P<0.05; ***P<0.001; n= 16/group.

60

MMP-8 and MMP-9 correlated with DKA severity
In order to determine correlations between altered MMP/TIMP levels in DKA
plasma and a clinically relevant parameter, correlation analysis was applied to data points
graphed as MMP concentrations versus blood pH (acidotic blood pH reflects greater
DKA severity). Both MMP-8 and MMP-9 were inversely correlated with blood pH
(Figure 2-2A; rs= -0.71; P < 0.01 and Figure 2-2B, rs= -0.60, P < 0.05, respectively). In
contrast, no correlations could be determined for either MMP-2 or TIMP-4 (rs= 0.26, P=
0.34 and rs= 0.07, P= 0.80, data not graphically shown). These results suggest that MMP8 and MMP-9 plasma levels are correlated with DKA severity.
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FIGURE 2-2. Plasma MMP Correlation with pH in DKA. MMPs correlate with
DKA severity. (A) MMP-8 plasma concentrations were inversely correlated with blood
pH in DKA patients. A best-fit line was added to aid in visual interpretation of the graphs
(rs= -0.714, P= 0.0019, n= 16). (B) MMP-9 plasma concentrations were inversely
correlated with blood pH in DKA patients. A best-fit line was added to aid in visual
interpretation of the graphs (rs= -0.6024, P= 0.0135; n= 16).
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Leukocyte mRNA expression of MMPs and TIMPs
To determine whether the observed changes in MMP-2, MMP-8, MMP-9 and
TIMP-4 were leukocyte derived, we assayed the respective gene mRNA levels with
qPCR. MMP-8, MMP-9 and TIMP-4 gene expression was significantly increased in
leukocytes from DKA patients, as compared to CON patients (Figure 2-3; 45.0, 6.3 and
31.8 fold-change respectively; P < 0.0025). In contrast, MMP-2 showed no significant
changes. These results suggest that elevated plasma MMP-8, MMP-9 and TIMP-4 are, at
least in part, leukocyte derived.
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FIGURE 2-3. Leukocyte MMP Gene Expression in DKA. Elevated MMPs/TIMP-4
in DKA plasma are leukocyte-derived. Gene expression of MMP-8, MMP-9 and TIMP-4
were significantly elevated in DKA, as compared to CON patients. Target gene
expression is normalized to β-actin and GAPDH and presented as fold-change from
CON. N.S.: not significant; **P < 0.005 (controlled for repeated measures); n= 5/group
for MMP-2, n= 7/group for all other genes. Mean CT values for CON and DKA samples
were MMP-2 (37.73; 37.35), MMP-8 (29.91; 35.09), MMP-9(25.83; 28.11), TIMP-4
(39.40; 43.08), respectively.
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2.4 Discussion
In this study, we report that DKA induced a markedly altered plasma MMP/TIMP
profile in acute pediatric DKA patients, and that both MMP-8 and MMP-9 concentrations
correlated with DKA severity. DKA-induced MMPs were, at least in part, leukocyte
derived. MMP-8 and MMP-9, at concentrations similar to those measured in DKA
plasma, have been reported to disrupt brain endothelial cell tight junctions. To our
knowledge, this study is the first to employ human DKA tissues in relation to
pathological changes in systemic proteases.
Our current data, taken together with our previously reported results (10), show
that DKA is an inflammatory state associated with highly elevated levels of systemic
cytokines (IL-6 and IFN-α2), chemokines (CXCL-1 and CXCL-8) and MMPs (i.e.,
MMP-8 and MMP-9). MMPs have diverse actions that that may involve exacerbation of
existing inflammatory cascades (26), as well as direct actions on the microvasculature
(27). This latter action of MMPs is particularly intriguing given that DKA induced
leukocyte adherence to the brain microvasculature (10) and that the DKA-induced MMPs
appear to be leukocyte-derived.
MMP-8 was significantly elevated in DKA plasma and plasma MMP-8
concentrations correlated with DKA severity. MMP-8 mRNA was elevated in leukocytes
from DKA patients, a finding that is consistent with the almost exclusive production of
MMP-8 by neutrophils (28, 29). The primary substrates for MMP-8 are the fibrillary
collagens, I, II, III, as well as other extracellular matrix components (13). Vascular
leukocyte trafficking and blood brain barrier disruption are mediated by MMP-8, and
may involve cleavage of the endothelial cell tight junction proteins (30, 31). Our results
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raise the possibility that the DKA-induced elevations in MMP-8 may contribute to
cerebrovascular endothelial perturbations.
MMP-9 was significantly increased in DKA plasma and plasma MMP-9 activity
on zymogram correlated with DKA severity. The 100 kDa MMP-9 band suggests that the
plasma MMP-9 is primarily a latent form (32, 33), but it is available for immediate
activation. Neutrophils are a likely source of MMP-9 in DKA plasma given that increased
MMP-9 mRNA was found in our leukocyte preparation, that a ~135 kDa band was
observed on zymography that likely reflects a well-described complex of MMP-9 with
neutrophil-gelatinase-associated lipocalin (25), and that early rises in plasma MMP-9
have been attributed to neutrophil degranulation of stored MMP-9 (34). Delayed sources
of plasma MMP-9 may include de novo synthesis via monocytes, lymphocytes, dendritic
cells and endothelial cells (35). CXCL-8, known to be elevated in DKA, stimulates
expression of MMP-9 (36, 37). MMP-9 can proteolytically degrade virtually all
components of the extracellular matrix, and MMP-9 has the ability to disrupt components
of junctional complexes in the brain microvasculature (27, 38).
Our data suggests that plasma MMP-2 (~70 kDa) is decreased in DKA, possibly
due to the hyperglycemic conditions that are characteristic of DKA (39). Decreased
MMP-2 facilitates increased extracellular matrix deposition in vascular structures as a
primary function of MMP-2 is extracellular matrix turnover (40). Indeed, decreased
plasma levels of MMP-2 during DKA may contribute to chronic thickening of basal
lamina and pathologic remodeling of the extracellular matrix over multiple DKA
episodes.
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Plasma TIMP-4 was also mildly elevated in DKA and was at least partially
leukocyte-derived. Increases in TIMP-4 are likely due to increased monocytic expression.
While TIMP-4 is considered a broad MMP inhibitor, it also displays some specificity
against MMP-2 (41) and has the ability to prevent cell surface activation of MMP-2 (42).
Depressed levels of MMP-2, in conjunction with elevated plasma TIMP-4, could
facilitate extracellular matrix deposition.
The actions of elevated plasma MMP-8 and MMP-9 in DKA are largely
unknown. The main role attributed to MMPs during inflammation is its proteolytic ability
on cellular junctions, however, MMPs are now known to play a role in cytokine
processing and generation of biologically active or inactive fragments (26). Processing of
the DKA-relevant chemokine CXCL-8 (10), by both MMP-8 and MMP-9, has been
shown to potentiate its chemotactic effects and biological function (43), MMP-mediated
cytokine processing acts to facilitate leukocyte migration, thus facilitating endothelial
disruption indirectly (26).
Higher concentrations of plasma MMP-8 and MMP-9 were associated with
greater DKA severity (lower pH). Acidic pH directly stimulates the induction and release
of cellular MMPs (44-47), and a lower pH is associated with markedly more MMP-8 and
MMP-9 catalytic activity (44, 48-50). Thus, DKA patients, by virtue of their blood acidic
pH, are particularly susceptible to the deleterious actions of MMP-8 and MMP-9. DKA
correction with intravenous fluid and exogenous insulin administration normalizes the
blood pH. While MMP-8 activity would decrease with increasing pH to normal values
(48, 50), MMP-9 still maintains much of its catalytic activity (44, 49). In contrast, MMP-
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2 is noted to have decreased activity in acidic pH conditions (51), perhaps resulting in
further reduced MMP-2 functional capacity.
MMPs have been shown to increase permeability of human brain microvascular
endothelium (i.e., vasogenic edema) (18, 19), likely by degrading tight junction proteins,
including occludin, claudin-5 and ZO-1 (17). Active MMP-9 has been most thoroughly
investigated, and exerts actions at concentrations (100-250 ng/ml) that are compatible
with those measured for latent MMP-9 in DKA plasma (1,509 ng/ml) (17, 18). The
sequential addition of MMPs (i.e., MMP-8) has been demonstrated to boost substrate
degradation (52).
Our study has several limitations worthy of discussion. First, our data showed a
leukocyte origin of the MMP-8 and MMP-9, but we cannot rule out other cellular
contributions (i.e., endothelial cells). Future studies should try to isolate leukocyte
subtypes for analyses from fresh blood samples. Second, the measured concentrations of
MMP-8 and MMP-9 might not represent the exact concentrations encountered at the
brain endothelial cell layer. The MMP concentrations adjacent to leukocytes adhered to
the brain microvascular endothelium are almost certainly higher, but we have no way of
measuring concentrations in such localized domains.
In summary, our data show for the first time that DKA is a disease state
associated with dynamic regulation of plasma MMPs. In particular, leukocyte-derived
MMPs (e.g., MMP-8 and MMP-9) correlated with disease severity and they have the
potential to degrade key components of the cerebrovascular tight junctions, perhaps
explaining the susceptibility of children with DKA to intracranial complications. Our
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data, provide a plausible mechanism for DKA-induced cerebrovascular perturbations, and
represents a possible link between DKA mediated inflammation and DKA
cerebrovascular crises.
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CHAPTER 3: ELEVATED LEUKOCYTE AZUROPHILIC ENZYMES IN
HUMAN DIABETIC KETOACIDOSIS PLASMA DEGRADE
CEREBROVASCULAR ENDOTHELIAL JUNCTIONAL PROTEINS
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3.1 Introduction
Type 1 diabetes mellitus (T1DM) is a chronic affliction that occurs primarily in
children, whose diagnosis has been occurring at an increasingly younger age (1, 2). A
serious complication of T1DM is diabetic ketoacidosis (DKA), which results from severe
insulin deficiency. DKA refers to the triad of metabolic acidosis, hyperglycemia and
ketonemia (3). Intracranial cerebrovascular complications such as stroke (4), hemorrhage
(5, 6) and cerebral edema (7, 8) have all been shown to be associated with DKA in
children. Previous work in our lab has shown that DKA is associated with a systemic
inflammatory response that stimulates polymorphonuclear neutrophil (PMN) adherence to
the brain microvascular endothelium via CXCL-1/CXCL-8 (9, 10).
PMN antimicrobial/proteolytic enzymes are normally stored safely in azurophilic
granules (11). Upon inflammatory stimulation, PMN undergo degranulation and granules
containing azurophilic enzymes (e.g., leukocyte elastase [HLE], proteinase-3 [PR-3],
cathepsin G [CTSG] and myeloperoxidase [MPO]) are released by activated circulating
or adherent PMNs. Elevated azurophilic enzymes produced by adherent PMNs may
contribute to degradation of the vascular element and potentially contribute to
destabilization of the BBB (12, 13).
We hypothesized that DKA is associated with elevated PMN azurophilic enzymes
and that some or all of these enzymes may lead to BBB dysfunction. Thus, our aims using
human DKA blood were: (1) to measure plasma levels of PMN azurophilic enzymes, (2)
to determine any relationships between enzyme levels and DKA severity and (3) to
determine the consequential effects of enzyme levels on cerebrovascular endothelial
junctional proteins in vitro.
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3.2 Methods
This study was approved by the Health Sciences Research Ethics Board at
Western University. Patients were recruited at our regional tertiary care centre; the
Children’s Hospital, London Health Sciences Centre (London, ON).
3.2.1 Human Subjects
Consent was obtained from the legal guardians of all pediatric patients admitted
with DKA, and both legal guardian consent and patient assent were obtained for type-1
diabetes control patients. Biochemical diagnostic criteria for DKA include hyperglycemia
> 11 mmol/L, bicarbonate < 15 mmol/L and ketonurea (14). DKA is classed according to
severity of acidosis as mild DKA (venous pH < 7.3), moderate DKA (pH < 7.2) or severe
DKA (pH < 7.1) (15, 16). A majority of DKA cases used in this study were severe. Clinic
patients with insulin controlled type-1 diabetes (HbA1c < 10% and no DKA for at least 3
months) served as controls (CON).
3.2.2 Blood Collection and Processing
Blood for research purposes was obtained on hospital presentation at the time of
clinically-indicated blood draws. Blood was drawn into citrate-containing tubes
(Vacutainers®, BD Biosciences, Mississauga, ON) by certified nursing personnel, placed
on ice, and immediately transferred to the Translational Research Centre facility for
processing by standard operating procedures (www.translationalresearch.ca, London,
ON) (17, 18). Briefly, blood was centrifuged at 1500 g for 15 min (4oC), and the upper
plasma layer was collected in 250 µl aliquots and frozen at −80 °C. Thawed plasma was
maintained on ice for short periods prior to use in experiments and freeze-thaw cycles
were avoided.
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3.2.3 Polymorphonuclear Neutrophil Enzyme Measurement
The plasma concentrations of several major PMN-associated enzymes were
measured via enzyme-linked immunosorbent assay (ELISA) in patients. We measured the
plasma concentration of the serine proteases human leukocyte elastase (HLE; 1:100
dilution; Abcam, Cambridge, UK), proteinase-3 (PR-3; 1:30 dilution; Cloud-Clone Corp.,
Houston, TX) and cathepsin G (CTSG; undiluted; MyBioSource, Inc., San Diego, CA).
The plasma concentration of myeloperoxidase (MPO; 1:1 dilution; Abcam) as a marker of
PMN activation was also assessed. Concentrations were adjusted for dilution factor.
3.2.4 Cell Culture
Primary human brain endothelial primary cells (hBMEC) were kindly provided by
Dr. Mahmud Bani (NRC, Ottawa, ON) and used as a model of brain microvascular
endothelium in vitro. hBMEC were cultured in EBM-2 Endothelial Growth Basal
Medium (Clonetics®; Lonza) supplemented with Clonetics® EGM®-2 MV SingleQuots
kit (Lonza), 1% GA-1000 (Lonza) on gelatin (0.5% w/v in water; Sigma-Aldrich) coated
plates. The cells were maintained at 37°C in a humidified atmosphere with 5% CO2 and
reseeded when the cell monolayer became sub-confluent. hBMEC at passage 2-15 were
used in all experiments. For treatments, hBMEC were seeded into 24-well plates (8.0×105
cells/well) and grown until confluence.
3.2.5 In vitro Experimental Approach
hBMEC monolayers were treated with human neutrophil PR-3 (Athens Research
& Technology, GA), HLE (Abcam) and MPO (Abcam) diluted in serum-free VascuLife®
basal medium (VL; Lifeline Cell Technology). Growth media was aspirated and wells
were treated with basal medium only (-), HLE (2 µg/mL) (19), PR-3 (5 µg/mL) (20, 21)
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or MPO (35 ng/mL) (22) by themselves or all in combination (Total) for 1 hour at 37°C
(5% CO2). MPO-treated wells (MPO and Total) were supplemented with 80 µM H2O2 to
provide a substrate for free radical generation.
3.2.6 Immunoblotting
Degradation of zonula occludens-1 (ZO-1) and β-catenin were assessed using
immunoblotting. Following protease treatment, wells were washed 3 times with ice-cold
phosphate buffered saline (PBS) then lysed in 200µL of hot SDS-electrophoresis sample
buffer. Samples were then stored at -20°C. Prior to running, samples were boiled for 5
minutes then electrophoresed with 10% SDS-polyacrylamide gel electrophoresis. Proteins
were transferred overnight to a BioTrace polyvinylidene diflouride (PVDF) membrane
(Pall Corporation, Port Washington, NY). Following transfer, the membranes were
blocked in 5% skim milk in 0.1% Tween tris-buffered saline (TBST) for 1 hour at room
temperature. Membranes were then incubated with primary antibody, polyclonal rabbit
anti-ZO-1 (mid) 1:2000 (Invitrogen, Carlsbad, CA) or polyclonal rabbit anti-β-catenin
1:4000 (Abcam, Cambridge, UK) in 2% skim milk in tris-buffered saline (TBS) for 2
hours at room temperature. The membrane was then washed 3 times for 5 min each with
TBST then incubated with secondary horseradish peroxidase-conjugated antibody, goat
anti-rabbit (Invitrogen) in 2% skim milk in TBS for 1 hour at room temperature. Finally,
membranes were washed for 5 min twice and then 10 min with TBS. For a loading
control, each membrane was also probed with monoclonal anti-lamin-β1 (Abcam). Bound
target antibodies were visualized using enhanced chemiluminescence detection (2.5mM
Luminol, 0.4mM p-coumaric acid, 0.02% H2O2 in 100mM Tris buffer; Sigma-Aldrich).
Images of the immunoblots were captured using a MicroChemi imaging system
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(Froggabio) and band quantification was done with GelQuant Pro Software (Froggabio).
Target bands were quantified as an optical density (O.D.) ratio to its corresponding laminβ1 band.
3.2.7 Quantification of Monolayer Detachment
To determine whether there was significant hBMEC detachment following PMN
enzyme treatment, we quantified the number of cells present in the culture media
following treatment. hBMEC were grown on gelatin-coated 24-well plates until the
monolayer reached confluency. Cells were treated for 1 hour at 37°C with PMN enzymes.
Subsequently, the culture media from wells were collected into microtubes. Samples were
centrifuged at 20,000 g for 10 minutes, supernatant discarded and pellets were
resuspended in cold 0.4% Trypan Blue in PBS. Cells were resuspended in a much smaller
volume (10X concentrated) relative to the original sample volume to allow for a more
accurate cell counting. The number of cells in each sample was counted using a
Haemocytometer (Hausser Scientific, Horsham, PA) and expressed as the number of cells
detached per well.
3.2.8 Statistical Analysis
Data was screened for normality and assessed with either the Mann-Whitney U
test (nonparametric data) or the Student’s t-test (parametric data). For multiple
comparisons, the Kruskal-Wallace test with post-hoc Tukey test (nonparametric data) or a
One-Way Analysis of Variance (ANOVA) test with post-hoc Holm-Sidak test (parametric
data) was used. Correlation analysis utilized the Spearman’s rank correlation coefficient.
All data is presented as mean ± SEM, statistical significance (P < 0.05).
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3.3 Results
Study patients
Plasma was obtained from type-1 diabetes patients either in acute DKA or an
insulin-controlled state (CON). The two groups were age- and sex-matched (Table 3-1;
n= 16 patients/group). Patients with DKA had significantly higher HbA1C values,
compared to those with controlled type-1 diabetes (P < 0.001), indicating elevated blood
glucose over the previous three months. DKA patients all had elevated blood glucose
(27.4 ± 8.3 mmol/L) and metabolic acidosis on blood gas measurements (pH 7.00 ± 0.03;
PCO2 20.8 ± 2.3 mmHg; HCO3- 5.9 ± 0.8 mmol/L; lactate 2.9 ± 0.7 mmol/L).
DKA patients had an elevated complete blood leukocyte count (Table 3-2; n= 16)
relative to age-specific normal ranges. Specifically, all DKA patients had neutrophilia and
monocytosis (n= 14; Two patients did not have a differential WBC count done).
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TABLE 3-1. Human Clinical and Biochemical Data for Type-1 Diabetes
Patients
Insulin Controlled (CON) or with Acute Diabetic Ketoacidosis (DKA). (n=
16/group)
CON

DKA

Mean age (years)

11.4 ± 1.0

11.7 ± 0.8

0.83

Male: female ratio

8:8

8:8

1.00

HbA1c (%)

8.3 ± 0.3

11.7 ± 0.5

pH

N/A

7.00 ± 0.03

HCO3- (mmol/L)

N/A

5.9 ± 0.8

pCO2 ( mmHg)

N/A

20.8 ± 2.3

Lactate (mmol/L)

N/A

2.9 ± 0.7

Blood glucose (mmol/L)

N/A

27.4 ± 8.3

Data presented as mean ± SEM.
a; Boldface indicates significant P value (P < 0.05). N/A; data not gathered

P value

< 0.001
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TABLE 3-2. Differential White Blood Cell Count for DKA Patients
Healthy
Reference Range
Cell type
Leukocytes, total (x109/L)

n= 16

Status

22.99 ± 2.16

4.0-10

Elevated

Neutrophils (x109/L)

18.43 ± 1.96

4.0-5.3

Elevated

Lymphocytes
(x109/L)

2.04 ± 0.17

1.4-4.0

Normal

Monocytes (x109/L)

1.54 ± 0.19

0.2-0.8

Elevated

Eosinophils (x109/L)

0.02 ± 0.01

0.0-0.8

Normal

Basophils (x109/L)

0.11 ± 0.01

0.0-0.1

Normal

Data presented as mean ± SEM.
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Polymorphonuclear neutrophil enzyme measurements
In order to assess PMN degranulation, plasma levels of the major azurophilic
granule enzymes were investigated. The concentration of HLE, PR-3, CTSG and MPO
was measured in DKA and CON plasma. It was found that HLE was significantly
increased in DKA plasma (85.99 ng/mL) compared to CON plasma (31.61 ng/mL; P <
0.001; Figure 3-1A). PR-3 was significantly increased in DKA plasma (27.04 ng/mL)
compared to CON plasma (8.87 ng/mL; P < 0.001; Figure 3-1B). CTSG was assessed but
found to be not significantly changed between CON and DKA plasma (P=0.81; Figure 31C). MPO, a major component of the PMN oxygen-dependent antimicrobial pathway,
was significantly increased in DKA plasma (5.49 ng/mL) compared to CON plasma (3.25
ng/mL) (P < 0.001; Figure 3-1D).
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FIGURE 3-1. Plasma Leukocyte Azurophilic Enzymes in DKA. DKA plasma was
associated with increased circulating PMN enzymes. Circulating HLE increased in DKA
plasma compared to CON plasma (A). The average concentrations in CON and DKA
plasma were 31.6 ng/mL and 85.99 ng/mL, respectively. PR-3 was also increased
significantly in DKA plasma compared to CON plasma (B). The average concentrations
for CON and DKA were 8.87 ng/mL and 27.04 ng/mL, respectively. CTSG was not
significantly changed between CON and DKA groups (C). Finally, MPO increased in
DKA plasma compared to CON (D). Observed concentrations were 5.49 ng/mL and 3.25
ng/mL, respectively. N.S. not significant; **P < 0.01; ***P < 0.001; n= 14 per group (A);
n= 15 per group (B); n= 16 per group (C, D).
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PR-3 was inversely correlated with blood pH
In order to determine the relationship between level of significantly altered plasma
PMN azurophilic enzymes in DKA samples and disease severity, correlation analysis was
applied to data points graphed as concentration versus blood pH which was used as a
surrogate of DKA severity. Plasma PR-3 (Figure 3-2B) concentration in DKA was found
to be significantly inversely correlated with blood pH (rs = 0.73, P < 0.01). In contrast, no
correlation could be detected for HLE (Figure 3-2A) or MPO (Figure 3-2C) (rs= -0.24, P=
0.41 and rs= 0.06, P= 0.82, respectively).
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FIGURE 3-2. Plasma PMN Azurophilic Enzyme Correlation with pH in DKA.
PR-3 was significantly correlated with disease severity. Correlation analysis was applied
to the concentration of the 3 significantly increased PMN azurophilic enzymes, HLE, PR3 and MPO in DKA plasma with blood pH. Only PR-3 concentration displayed
significant inverse correlation with blood pH (rs= -0.7317, P= 0.002, n= 15) (B). Both
HLE (rs= -0.24, P= 0.41, n= 14) (A) and MPO (rs= 0.06, P= 0.82, n= 16) (C) were not
significantly correlated with blood pH. A line of best fit was added to the graphs to aid in
interpretation of the data points.
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PMN enzymes disrupt ZO-1 and β-catenin in vitro
Elevated PMN enzymes were applied to hBMEC monolayers in order to assess
their effect on protein junctions. Specifically, we investigated degradation of both ZO-1
and β-catenin, critical structural elements of TJs and AJs, respectively. PR-3 and total
enzyme mixture both significantly decreased ZO-1 expression (Figure 3-3A, B; P < 0.05,
P <0.01, respectively). No changes were seen in regards to ZO-1 degradation products.
PR-3 and total enzyme mixture also both significantly increased the appearance of
smaller molecular weight β-catenin degradation products (Figure 3-3C, D; P < 0.01 and P
< 0.001, respectively). No significant changes were seen with regard to full length βcatenin. H2O2 by itself as a control did not have an effect on either ZO-1 or β-catenin, full
length or degradation (Data not shown). The changes in protein levels were not due to cell
detachment from the monolayer as there were no changes in the number of detached cells
in treatment media following treatment (P= 0.60; n= 3; Data not shown).
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FIGURE 3-3. Enzyme-Mediated Degradation of ZO-1 and β-Catenin. An enzyme
cocktail mixture consisting of HLE, PR-3 and MPO was able to degrade β-catenin.
hBMEC monolayers were treated with a combination of significantly elevated PMN
azurophilic enzymes; (-), basal media only; HLE, 2 µg/mL HLE; PR-3, 5 µg/mL PR-3;
MPO, 35 ng/mL MPO + 80 µM H2O2; Total, 2 µg/mL HLE + 5 µg/mL PR-3 + 35 ng/mL
MPO + 80 µM H2O2. Representative blots for ZO-1 and β-catenin are shown in (A) and
(C), respectively. Full length ZO-1 expression (B) was significantly decreased by PR-3
treatment and total enzyme treatment whereas full length β-catenin (D) was not
significantly altered. No significant ZO-1 degradation products were observed (B). Total
enzyme mixture and PR-3 treatment resulted in an increase of a range of smaller
molecular weight β-catenin degradation bands (D). *P < 0.05, **P < 0.01, ***P < 0.001;
n= 7-8.
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3.4 Discussion
In this present study, we report that DKA is associated with elevated neutrophils
and induces increased PMN degranulation. While HLE, PR-3 and MPO were all elevated
in DKA plasma, only PR-3 was positively correlated with DKA severity. PR-3 alone, or
in combination with the other PMN enzymes, resulted in decreased expression of the tight
junction protein ZO-1 and degradation of the adherens junction protein β-catenin in vitro.
To our knowledge, this study is the first to employ human DKA tissues in relation to
pathological changes in systemic PMN azurophilic enzymes.
In this study, the differential white blood cell count of DKA patients showed
monocytosis and neutrophilia, consistent with previous reports of increased circulation of
leukocytes during DKA (23, 24). Also, we show that PMN in acute DKA patients
undergo degranulation with the release of azurophilic granule-specific enzymes, HLE,
PR-3 and MPO. Ubiquitous PMN activation in DKA patients is in direct agreement with
our previous work that showed increased PMN-endothelial adherence due to the
cytokines CXCL-1 and CXCL-8 (10) as well as DKA-induced regulation of leukocytederived MMPs (Chapter 2).
The increased circulating enzymes, HLE, PR-3 and MPO, are relevant to
intracerebral complications as there is evidence linking them to endothelial perturbation
(25-28). HLE can disrupt junctional proteins such as E-cadherin (19, 25, 29) and βcatenin (30) and break down components of the extracellular matrix (31, 32). HLE has
also been shown to facilitate PMN transmigration, thereby contributing to endothelial
disruption indirectly (33). HLE can also activate MMP-9 (34, 35), thus potentiating the
destructive effects of the MMPs that we have shown to be elevated in DKA plasma
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(Chapter 2). The presence of extracellular PMN enzymes may also affect endothelial
stability indirectly; HLE has also been shown to induce CXCL-8 expression (36, 37)
which has been shown to facilitate PMN adherence to the endothelium in DKA (10).
PR-3 is also involved in PMN transmigration (38), and MMP activation (35). PR3 has been shown to potentiate the effects of CXCL-8 by cleavage into a more potent
form (39). Only PR-3 was positively correlated with DKA severity. This latter finding
may be due to PMN activation by acidic extracellular pH as it has been shown that a sub
fraction of PMN PR-3 localizes not to azurophilic granules but to secretory vesicles (40,
41). Secretory vesicles are the first vesicles to be released by PMN following stimulation
and tend to be released in a dose-dependent manner (42). These vesicles are released
faster than azurophilic granules and so it is conceivable that only PR-3, at this stage in
DKA progression, is released in a pH-dependent manner
Through its ability to generate hypohalous acid, MPO can facilitate endothelial
dysfunction, both in vitro and in vivo (22, 28, 43), as well as degrade the endothelial
extracellular matrix (26). Hypochlorous acid generated by MPO can activate MMP-9
(44), and MMP-9 was elevated in DKA (Chapter 2). Apart from its oxidative compoundgenerating ability, MPO facilitates leukocyte activation and adhesion to the endothelium
during inflammation (45, 46).
In support of the notion that PMN azurophilic enzymes contribute to vascular
dysfunction in DKA, a total enzyme cocktail containing significantly increased
azurophilic enzymes, HLE, PR-3 and MPO decreased ZO-1 expression in brain
microvascular endothelial cells in vitro. ZO-1 is an integral component of the tight
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junction as it anchors both occludin and claudin to the actin cytoskeleton and is important
for junctional regulation (47). Reduced expression of ZO-1 facilitates endothelial
permeability (48-50).
Our total enzyme cocktail also degraded β-catenin in human brain endothelial
cells. β-catenin is one of the terminal cytoplasmic proteins in the adherens junction. Its
role is to anchor the intercellular component VE-cadherin to the cytoskeleton and it is
responsible for junctional regulation (51). β-catenin loss is associated with vascular
instability and hemorrhage (52). However, we did not observe a significant decrease in
full length β-catenin concurrently with appearance of the degradation products, indicating
increased protein turnover as opposed to only protein breakdown. Also, since we did not
observe any enzyme-mediated degradation products with ZO-1, this implies that βcatenin and ZO-1 are differentially processed. These changes most likely occurred
through extracellular-intracellular signalling as it has been shown that disruption of both
the membrane-bound proteins occludin and VE-cadherin result in disruption of their
cytosolic counterparts (53, 54).
The concentrations of PMN enzymes used in our in vitro experiments were greater
than what we measured in plasma. Physiologically, PMN degranulation occurs at the
endothelial surface, or inside the intercellular compartment. In actuality, the
concentrations at the endothelium of PMN-derived molecules are almost certainly greater
than those that we measured in plasma. In fact, HLE (55, 56), lactoferrin and defensins
(57) and cytokines (58) have been suggested to reach local concentrations of up to 2
mg/ml, following PMN degranulation. The levels of enzymes we measured in plasma are
most likely “spill over” from more localized domains and would be diluted as compared
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to the effective concentrations at the level of the endothelium. Therefore, we used enzyme
concentrations used in other publications (19-22)
As neutral proteases, both HLE and PR-3 may display slightly reduced catalytic
activity at acidic pH but as pH is normalized during DKA treatment, HLE and PR-3
activity would increase (59, 60). Our observation that PR-3 release is correlated with a
lower pH raises the possibility that increased PR-3 release under acidotic conditions may
compensate for decreased catalytic activity. MPO is known to be more active under acidic
conditions as well, thereby potentiating its ability to generate oxidative compounds in
DKA patients prior to treatment (61).
This study has several limitations. First, we assumed that HLE and PR-3 were of
PMN origin due to their release concurrent with PMN-specific MPO. Other notable
plasma sources of HLE and PR-3, however minor, include endothelial cells (62) and
monocytes (63). Future studies should examine specific leukocyte components isolated
from DKA patients. Second, the release and maximal effects of the individual enzymes,
HLE, PR-3 and MPO during DKA and its treatment are currently unknown and require
further examination.
We have shown previously that pediatric DKA is associated with inflammation
and PMN adherence to brain microvascular endothelial cells. We now demonstrate
increased circulating PMN azurophilic enzymes (HLE, PR-3 and MPO) that reduced the
expression of the tight junction protein, ZO-1 and degraded the adherens junction protein,
β-catenin. These findings support the notion of DKA as an inflammatory condition and in
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conjunction with our other work (10), implicates PMN activation and degranulation in
DKA-associated BBB disruption.
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4.1 Discussion
DKA is associated with intracerebral vascular complications in children, such as
stroke (1), hemorrhage (2) and cerebral edema (3). The mechanisms of these
complications are not well known.
DKA is an inflammatory condition involving increases in circulating cytokines
such as CXCL-1 (GROα), CXCL-8 (IL-8), IL-6 and IFN-α2 (4). These cytokines are
known to cause activation of leukocytes, including PMN (5). Thus, I hypothesized that
during pediatric DKA, inflammation leads to widespread activation of leukocytes which
then release destructive enzymes. This enzyme surge could be responsible for facilitating
cerebrovascular damage.
In this thesis, we observed alterations in the plasma level of a number of MMPs
and TIMP-4 as well as PMN azurophilic enzymes. DKA plasma was associated with
decreased MMP-2 and increased MMP-8, MMP-9 and TIMP-4. DKA plasma was also
associated with increased PMN azurophilic enzymes, HLE, PR-3 and MPO. Our findings
are consistent with a widespread inflammatory condition occurring in DKA patients.
HLE, PR-3 and MPO are major components of PMN azurophilic granules, which are
only released upon degranulation following PMN activation (6). In fact, MPO is
exclusively a component of the PMN azurophilic granules and as such is widely utilized
as a marker for PMN activation. MMP-8 is found in the PMN secondary granules (7) and
is released upon activation as well, albeit earlier in inflammation than the other PMN
enzymes (8). Interestingly, active transcription of MMP-8 is thought to occur only in
immature PMN, indicating mobilization from bone marrow of immature PMN during
DKA: a hallmark of an overwhelming inflammatory response (6). MMP-9 is, among
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other sources, associated with the PMN tertiary granule. Further support for notion of
PMN-associated MMP-9 comes from the detection of lipocalin-associated MMP-9
complex in DKA plasma, characteristic of PMN-associated MMP-9.
The plasma levels of MMP-8, MMP-9 and PR-3 were positively correlated with
DKA severity. The aforementioned correlations are in agreement with studies that have
shown that acidic pH directly stimulates release of MMPs from cells (9-11) and leads to
enhanced PMN activation (12). The severity of acidosis during DKA has previously been
shown to be determinant of the magnitude of consciousness impairment. Cerebral
function in DKA patients with cerebral edema is closely tied to pH; a lower pH is
correlated with increased level of cognitive impairment (13). Our data supports the
notion that the relationship between pH and severity of DKA neurological impairment
may involve pathological regulation of MMP-8 and MMP-9 as well as PR-3.
We have shown that DKA plasma is associated with increased levels of MMP-8,
MMP-9, HLE, PR-3 and MPO. The presence of these enzymes at the level of the
endothelium could potentially lead to breakdown of the intercellular junctions and
facilitate fluid movement into the brain (e.g., vasogenic edema). Indeed, using human
brain microvascular endothelial cells, we have shown a potential role for PR-3, HLE and
MPO in disruption of both AJs and TJs. Numerous studies have implicated the MMPs
and PMN azurophilic enzymes in facilitating breakdown of the BBB (14-17).
Our data raises the possibility of a 2-stage insult to the brain microvasculature.
We have shown that DKA stimulates the release of MMP-8, MMP-9, HLE, PR-3 and
MPO. Following DKA-induced release of these enzymes, MMP-8 and MPO can be
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expected to display higher catalytic activity during the initial stages of DKA when blood
pH is low (18, 19). During treatment and the ensuing normalization of pH, the catalytic
activity of MMP-9 (20), HLE and PR-3 (21) can be expected to increase, potentially
leading to a second wave of protease activity.
These studies have provided insight into the circulating protease profile occurring
in pediatric DKA patients. Future studies could examine the effects on these enzymes in
vivo by assessing markers of BBB disruption in DKA plasma. Solubilized junctional
proteins in circulation like occludin, claudin-5 and cadherin might indicate cleavage and
subsequent release from the brain endothelium. Unfortunately, due to the ethical
ramifications of patient studies, it is difficult to probe more into the physiological
functions. The effects of these enzymes on BBB structure and function could be assessed
in vitro. Isolated PMN could be applied to human cerebromicrovascular endothelial
monolayers under DKA conditions (e.g., acidosis, hyperglycemia, and DKA-specific
cytokine mixture) in order to assess their direct effect on monolayer integrity. The effect
of PMN on the BBB could be assessed in a juvenile mouse model of DKA as well (22).
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FIGURE 4-1. Proposed Mechanism of PMN-Mediated DKA
Endothelial Perturbations. DKA is a well-known inflammatory
condition. Inflammatory cytokines in circulation serve to activate
endothelial cells and PMN, recruiting them to the endothelial surface.
PMN degranulate upon activation and the released proteases destroy
the junctions between adjacent cells. Released proteases may also
potentiate existing DKA-mediated cytokines, thereby facilitating a
positive feedback mechanism. This results in the loss of vascular
integrity, leading to fluid and solutes moving across the BBB, thus
facilitating DKA-mediated cerebrovascular dysfunction.
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